Skip to content
Medxy AI
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • sorafenib
Toripalimab Plus Bevacizumab vs Sorafenib as First-Line Therapy in Advanced Hepatocellular Carcinoma: Results from the Phase 3 HEPATORCH Trial
Posted inClinical Updates Wellness & Lifestyle

Toripalimab Plus Bevacizumab vs Sorafenib as First-Line Therapy in Advanced Hepatocellular Carcinoma: Results from the Phase 3 HEPATORCH Trial

Posted by By MedXY 08/02/2025
The HEPATORCH phase 3 trial demonstrates that toripalimab plus bevacizumab significantly improves survival outcomes versus sorafenib in previously untreated advanced hepatocellular carcinoma, with manageable safety.
Read More
  • Early Toxicity Comparison of Moderately Hypofractionated Radiotherapy and Stereotactic Body Radiotherapy in Prostate Cancer: Insights from the PACE-C Trial
  • Ten-Year Outcomes of Partial-Breast Radiotherapy After Breast Conservation Surgery: Insights from the UK IMPORT LOW Trial
  • Long-Acting Oral Weekly Risperidone (LYN-005): Translating Pharmacokinetic Equivalence to Clinical Opportunity in Schizophrenia
  • Semaglutide for Weight Management in Clozapine-Treated Schizophrenia: Results from the COaST Phase 2 RCT in Australia
  • Comparative Effectiveness of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide for Maintenance Therapy in HIV: Insights from the PASO-DOBLE Trial
  • About us
  • Contact us
  • Privacy Policy
  • Subscribe Now!
  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease Antibiotics breast cancer clinical trial clinical trials diabetes diagnosis diet exercise FDA FDA approval GLP-1 health healthcare HIV Hypertension immunotherapy lifestyle lifestyle intervention longevity maternal health men's health Menopause mental health nutrition obesity older adults PCOS Pediatrics Physical Activity Pregnancy prevention public health randomized trial semaglutide sexual health sleep stroke treatment type 2 diabetes walking weight loss wellness women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top